ClearSight LLC

Company Profile

**Industry Sector:** Medical Devices

**Company Overview:** ClearSight LLC (ClearSight) is a Colorado based-medical device company that is developing and commercializing a state-of-the-art intraocular lens (IOL). Through the marriage of two complimentary technologies, a novel IOL design combined with a unique micro-topography, the ClearSight IOL is designed to prevent the migration of lens epithelial cells (LECs) behind the IOL—the direct cause of posterior capsular opacification (PCO), one of the most frequent and costly ophthalmologic surgical complications.

**Target Market(s):**
- Ambulatory Surgical Centers
- Hospital Outpatient Departments of Ophthalmology
- Teaching Hospitals and VA Hospitals

Key Value Drivers

**Technology**: The ClearSight IOL furthers the golden-standard square-edge concept with a **novel 360° dual square-edge design** that fully surrounds and protects the optic against LEC migration. The **Sharklet** biomimetic micropattern, which, on its own, has been proven to control tissue cell migration, provides an additional protective mechanism.

**Competitive Advantage**: ClearSight will be the only preventative treatment for PCO on the market. Its non-toxic surface technology poses no unnecessary safety concerns and the one-piece design easily integrates into existing surgical practice, minimizing switching costs.

**Plan & Strategy**: ClearSight will continue to seek non-dilutive funding and private investment to bring the technology to a licensing agreement and/or acquisition.

Management

**Leadership:**
- Mark M. Spiecker — Manager
- Kevin H. Cuevas, M.D. — Chief Medical Officer
- Shravanthi Reddy, PhD — Chief Operating Officer

**Scientific Advisory Board:**
- Mark Packer, M.D. — Consultant & Medical Monitor
- Stephen Slade, M.D. — Consultant & Co-Investigator
- William Trattler, M.D. — Consultant & Co-Investigator
- Albert Parker, PhD — Lead Biostatistician

Product Development

**Development**
- 2016: Pre-Submission Meetings
- 2017: Complete Clinical Trial
- 2018: Submit results to obtain CE Mark

**Commercialization**
- Licensing Agreement, M&A

**Future IOL Pipeline:** Toric, Multifocal, Microelectronics (i.e. intraocular pressure monitor for glaucoma)